Peter Gottschalk, MD
Neurology · Fairfield, CTNPI 1831131176
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $205,860 of the $317,570 with a category attached, or 64.8%. 25 manufacturers reported payments, led by H. Lundbeck A S at 29.9% of the total. Reporting peaked in 2019 at $108,521 and has fallen 58.2% since, to $45,374 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $1034.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$95K
- Amgen$90K
- AbbVie$39K
- Lundbeck LLC$28K
- Lilly USA, LLC$27K
- Upsher-smith Laboratories LLC$8K
- plus $31K from 19 others
Across 6 payments — averaging $8228.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$39K
- Novartis$10K
What the payments were for
- Consulting fees$44,76914%
- Speaking & faculty fees$205,86065%
- Travel & lodging$59,17119%
- Food & beverage$7,7702%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 26 | $95,097 |
| Amgen | 101 | $90,132 |
| AbbVie(2 entities) | 45 | $38,500 |
| Lundbeck LLC | 26 | $28,405 |
| Lilly USA, LLC | 34 | $26,796 |
| Upsher-smith Laboratories LLC | 9 | $7,609 |
| Promius Pharma LLC | 6 | $6,885 |
| Impel Pharmaceuticals LLC | 9 | $4,845 |
| Biodelivery Sciences International, Inc. | 1 | $3,000 |
| Impel Pharmaceuticals Inc. | 4 | $2,768 |
| Tonix Medicines, Inc. | 6 | $2,738 |
| Novartis | 3 | $2,613 |
| Currax Pharmaceuticals LLC | 1 | $2,250 |
| Amneal Pharmaceuticals LLC | 1 | $2,000 |
| Teva Pharmaceuticals USA, Inc. | 2 | $1,544 |
| AstraZeneca | 1 | $860 |
| Dr.reddy's Laboratories,inc. | 1 | $449 |
| Pfizer | 12 | $330 |
| Biogen | 9 | $208 |
| Axsome Therapeutics, Inc. | 2 | $177 |
| Siemens Medical Solutions USA, Inc. | 1 | $171 |
| Avid Radiopharmaceuticals, Inc. | 2 | $56 |
| Assertio Therapeutics, Inc. | 1 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$92,365
- AIMOVIG$91,532
- UBRELVY$18,717
- EMGALITY$16,783
- ZEMBRACE SYMTOUCH$9,356
- Trudhesa$7,318
- Tosymra Sumatriptan Nasal Spray$6,067
- TOSYMRA$3,380
- ELYXYB - CELECOXIB$3,000
- Zembrace SymTouch Sumatriptan Injection$2,667
- ONZETRA XSAIL$2,250
- AJOVY$1,515
- BOTOX$925
- ARTIS icono biplane$171
- Symbravo$125
- QULIPTA$122
How this compares
$317,570 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 238 | $174,995 |
| Aimovig AutoinjectorErenumab-Aooe | 85 | $83,260 |
| QuliptaAtogepant | 60 | $73,721 |
| Nurtec OdtRimegepant Sulfate | 46 | $56,927 |
| UbrelvyUbrogepant | 40 | $54,193 |
| Methylergonovine Maleate | 13 | $31,684 |
| Sumatriptan Succinate | 142 | $25,016 |
| Zolmitriptan | 29 | $20,004 |
| OxycontinOxycodone Hcl | 11 | $15,361 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $13,899 |
| Ajovy SyringeFremanezumab-Vfrm | 16 | $12,802 |
| Carbamazepine ErCarbamazepine | 23 | $3,817 |
| Naratriptan Hcl | 90 | $2,734 |
| Eletriptan HbrEletriptan Hydrobromide | 51 | $2,434 |
| Gabapentin | 81 | $2,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $38,500 | $127,913100 claims |
| PfizerNurtec Odt | $330 | $56,92746 claims |
| Dr.reddy's Laboratories,inc.Pregabalin, Lamotrigine | $449 | $3,36187 claims |
| Upsher-smith Laboratories LLCTopiramate | $7,609 | $1,200128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.
Other neurology in Fairfield
- Peter McAllisterFairfield$2.3M
- Nicholas BlondinFairfield$93K
- Jeffrey GrossFairfield$52K
- Srinath KadimiFairfield$32K
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.